The company is investing $64.5 million to open new facilities in Germany and Japan to expand its overall capacity.
Minaris Regenerative Medicine, a contract development and manufacturing organization for cell and gene therapies, announced it is investing $64.5 million into the expansion of its facilities in Europe and Asia.
According to a company press release, the European expansion will focus on a new facility in Ottobrunn, Germany, for clinical and commercial manufacturing and development services for cell and gene therapies. Expected to be operational in 2023, the new site will offer additional cleanrooms, quality control laboratories, warehousing, cryo-storage, and office space.
The company is also opening a new facility in Yokohama, Japan to support its expansion in Asia, the press release said. The site will be dedicated to the commercial manufacturing of regenerative medicine and is set to be operational in October 2022.
“We are very pleased to expand our capacity to support the growing demand of clients who continue to care for an increasing number of patients in the future,” said Dusan Kosijer, managing director of Minaris Regenerative Medicine, in the press release.
Source: Minaris Regenerative Medicine
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.